Last reviewed 2026-05-28 · How we verify

Vistamycin (RIBOSTAMYCIN)

Phase 2 active Small molecule ✓ Verified May 2026 Quality 32/100

Vistamycin (generic name: RIBOSTAMYCIN) is a ribostamycin drug. It is currently in Phase 2 development.

Vistamycin works by binding to the 30S ribosomal subunit, inhibiting protein synthesis in bacteria.

Vistamycin, also known as Ribostamycin, is a small molecule antibiotic in the ribostamycin class. Its mechanism of action involves inhibiting protein synthesis in bacteria by binding to the 30S ribosomal subunit. However, due to the lack of available information, its target and approved indications are unknown. The commercial status of Vistamycin is also unclear, with no information available on its patent status or generic manufacturers. Further research is needed to determine its safety profile and potential uses.

Likelihood of approval

17.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Anti-infectives pathway favourability +2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	RIBOSTAMYCIN
Drug class	ribostamycin
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like factories that make proteins to keep you healthy. Bacteria are like tiny factories that make proteins too, but they're bad for you. Vistamycin is like a special tool that blocks the bacteria's factories from making proteins, helping to stop the infection.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Vistamycin CI brief — competitive landscape report
Vistamycin updates RSS · CI watch RSS

Frequently asked questions about Vistamycin

What is Vistamycin?

Vistamycin (RIBOSTAMYCIN) is a ribostamycin drug.

How does Vistamycin work?

Vistamycin works by binding to the 30S ribosomal subunit, inhibiting protein synthesis in bacteria.

What is the generic name of Vistamycin?

RIBOSTAMYCIN is the generic (nonproprietary) name of Vistamycin.

What drug class is Vistamycin in?

Vistamycin belongs to the ribostamycin class. See all ribostamycin drugs at /class/ribostamycin.

What development phase is Vistamycin in?

Vistamycin is in Phase 2.

Drug class: All ribostamycin drugs
Therapeutic area: All drugs in Infectious Disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing